ArticleProceedings of the National Academy of Sciences of the United States of America2021
Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances function of human islets.
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 45 citations in OpenAlex.
- A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.Nature communications · 2022Trial
- Intra-Islet Paracrine Regulation of Glucagon Secretion During Hypoglycemia, Euglycemia, and Hyperglycemia.Annals of the New York Academy of Sciences · 2026Review
- Pancreatic islet α cell function and proliferation require the arginine transporter SLC7A2.The Journal of clinical investigation · 2026Article
- Phosphodiesterase ENPP2, which is co-upregulated in obese and pregnant mice, is essential for islet beta cell compensation during obesity.Diabetologia · 2026Article
- scFv-based biologics in diabetes: from therapeutic potential to clinical prospects.Frontiers in immunology · 2026Review
- Regulation of Type 1 Diabetes via Brown Adipocyte-Secreted Proteins and the Novel Glucagon Regulator Nidogen-2.Diabetes · 2025Article
- Case-based learning: a case of maturity-onset diabetes of the young 5 (MODY5) due to 17q12 microdeletion with a diminished plasma glucagon level.Diabetology international · 2025Article
- Leukotriene B4 is elevated in diabetes and promotes ventricular arrhythmogenesis in guinea pig.Journal of cellular physiology · 2025Article
- Bi-Hormonal Endocrine Cell Presence Within the Islets of Langerhans of the Human Pancreas Throughout Life.Cells · 2025Article
- Article
- Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners.Molecular metabolism · 2024Article
- Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners.bioRxiv : the preprint server for biology · 2024Article
- ErbB3 is required for hyperaminoacidemia-induced pancreatic α cell hyperplasia.The Journal of biological chemistry · 2024Article
- Review
- Finishing the odyssey to a stem cell cure for type 1 diabetes.npj metabolic health and disease · 2024Review
- Targeting β-Cell Plasticity: A Promising Approach for Diabetes Treatment.Current issues in molecular biology · 2024Review
- Islet autoimmunity in human type 1 diabetes: initiation and progression from the perspective of the beta cell.Diabetologia · 2023Review
- A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome.Biomedicines · 2023Review
- Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice.Diabetes · 2023Article
- Prolonged control of insulin-dependent diabetes via intramuscular expression of plasmid-encoded single-strand insulin analogue.Genes & diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 1 country.
May-Yun WangTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
E Danielle DeanDivision of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0002-7157-5683
Ezekiel Quittner-StromTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.ORCID 0000-0002-0250-3475
Yi ZhuTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.ORCID 0000-0003-1650-1363
Kamrul H ChowdhuryDepartment of Nutrition and Integrative Physiology, University of Utah College of Health, Salt Lake City, UT 84112.
Zhuzhen ZhangTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.ORCID 0000-0001-6787-3920
Shangang ZhaoTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.ORCID 0000-0002-9209-8206
Na LiTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
Reshing YeTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
Young LeeTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
Yiyi ZhangTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
Shiuhwei ChenTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
Xinxin YuTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
Derek C LeonardTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
Greg PoffenbergerDivision of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0002-7363-4683
Alison Von DeylenDivision of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0002-9678-4393
S Kay McCorkleMedical Service, Veterans Administration North Texas Health Care System, Dallas, TX 75216.
Amnon SchlegelDepartment of Nutrition and Integrative Physiology, University of Utah College of Health, Salt Lake City, UT 84112.ORCID 0000-0003-4060-2252
Kyle W SloopDiabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Alexander M EfanovDiabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.ORCID 0000-0002-8630-1503
Ruth E GimenoDiabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Philipp E SchererTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.ORCID 0000-0003-0680-3392
Alvin C PowersDivision of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0003-1941-5786
Roger H UngerTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
William L HollandTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549; will.holland@hsc.utah.edu.
The University of Texas Southwestern Medical Center · USVA North Texas Health Care System · USEli Lilly (United States) · USUniversity of Utah · USVanderbilt University · USVanderbilt University Medical Center · US
Funding
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3MThe Human Islet Distribution Coordinating Center (UC4)UC4DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EVANS-MOLINA, CARMELLA, NILAND, JOYCE CAROL · 2012 to 2017
$25.6MSupplement to Integrated Program for Human Pancreas Procurement and AnalysisUC4DK112232 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., POWERS, ALVIN C · 2016 to 2020
$8.4MDiscovery of Pancreatic Signatures in Type 2 Diabetes MellitusR24DK106755 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAI, LONG, CAPRIOLI, RICHARD M · 2015 to 2019
$6.2MMolecular Mechanisms of Physiologic Beta Cell Growth in Juvenile Human PancreasUC4DK104211 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KIM, SEUNG K, POWERS, ALVIN C · 2014 to 2015
$4.0MMolecular Mechanisms of Postnatal Islet alpha-cell ProliferationR01DK117147 · NIDDK · VANDERBILT UNIVERSITY · PI CHEN, WENBIAO, POWERS, ALVIN C · 2019 to 2023
$3.1MSphingolipid-Mediated Dysregulation of Glucose and Energy Homeostasis in the CNSR01DK108833 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2016 to 2020
$1.8MAmino acid regulation of pancreatic islet alpha cell proliferation and functionK01DK117969 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DEAN, ERIKA DANIELLE · 2018 to 2021
$497kIslet alterations in type 2 diabetesI01BX000666 · VA · VETERANS HEALTH ADMINISTRATION · PI POWERS, ALVIN C · 2011 to 2025
–BLRD VA I01 BX000666NIDDK NIH HHS K01 DK117969NIDDK NIH HHS P30 DK020593NIDDK NIH HHS R01 DK108833NIDDK NIH HHS R01 DK117147NIDDK NIH HHS R24 DK106755NIDDK NIH HHS UC4 DK098085NIDDK NIH HHS UC4 DK104211NIDDK NIH HHS UC4 DK112232
Abstract
We evaluated the potential for a monoclonal antibody antagonist of the glucagon receptor (Ab-4) to maintain glucose homeostasis in type 1 diabetic rodents. We noted durable and sustained improvements in glycemia which persist long after treatment withdrawal. Ab-4 promoted β-cell survival and enhanced the recovery of insulin
Indexed as
AnimalsAntibodies, MonoclonalBlood GlucoseCell LineageCell TransdifferentiationC-PeptideDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Gene ExpressionGlucagonGlucagon-Secreting CellsHumansHypoglycemic AgentsInsulinInsulin-Secreting CellsIslets of LangerhansAntibodies, MonoclonalBlood GlucoseC-PeptideGlucagonHypoglycemic AgentsInsulinReceptors, Glucagondiabetesglucagoninsulinisletregeneration
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.